Protalix (NYSE: PLX) investors approve directors, pay and expanded stock plan
Rhea-AI Filing Summary
Protalix BioTherapeutics held its 2026 annual stockholder meeting, where investors approved all proposals presented. Stockholders elected eight directors, with Eliot Richard Forster, Ph.D. receiving 32,871,013 votes for and 2,379,140 withheld, alongside 10,705,177 broker non-votes.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 28,368,614 votes for and 6,683,937 against. They also approved an amended and restated 2006 Stock Incentive Plan, increasing the shares available under the plan from 17,475,171 to 20,975,171.
Stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 42,958,243 votes for, 2,001,734 against, and 995,352 abstentions.
Positive
- None.
Negative
- None.